MONTREAL--(BUSINESS WIRE)--Morphocell Technologies’ drive to create new clinical tools to treat currently untreatable liver conditions shifted into high gear this week with the impending addition of Dr. Jennifer Moody to its senior management team.
Dr. Moody is a stem cell commercialization and business operations expert with deep experience in the Canadian and global stem cell ecosystems, who most recently served as Senior Director of Research Operations at BlueRock Therapeutics in Toronto. She brings with her 23 years of experience in stem cell science, 13 of those years in industry commercializing products spanning from stem cell reagents to cell-based therapeutics.
Dr. Moody will assume the role of Morphocell’s Chief Operating Officer beginning October 7th, 2019.
“It has been several years since I first met the Morphocell team and I have enthusiastically followed their progress,” said Dr. Moody. “The vision and drive of the founding team has significantly progressed and de-risked their technologies. I am excited to be joining the team and look forward to contributing to the advancement of Morphocell’s proprietary engineered liver tissue to create a cell therapy product to address the significant unmet medical need that currently exists for liver disease.”
Morphocell is currently developing three revolutionary stem cell-derived products for use in acute, chronic and acute-on-chronic liver failure, which afflict millions worldwide:
- ReLiver® ELT: Implantable encapsulated liver tissue for acute/acute-on-chronic liver failure that is already in advanced pre-clinical assessment
- ReLiver® BALD: Extracorporeal bio-artificial liver replacement for patients with acute and chronic liver failure
- ReLiver® Assay: In vitro assay for next-generation drug discovery
“We are incredibly fortunate to add Dr. Moody to our team as we ramp up toward first-in-human clinical trials for ReLiver®ELT,” said Dr. Massimiliano Paganelli, pediatric transplant hepatologist at Sainte-Justine University Hospital Center in Montreal and co-founder of Morphocell. “She brings a whole new level of expertise and savviness to our R&D, clinical trial and commercialization programs and will be a tremendous collaborator going forward.”
About Morphocell Technologies
Morphocell is a Montreal-based start-up on a crusade to transform the treatment of liver disease. Preclinical assessments of the first effective stem cell-derived interventions for acute, chronic and acute-on-chronic liver failure are underway. www.morphocell.com / @MorphocellTech